home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc.

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...
CLRB - Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences,...

CLRB - Cellectar Biosciences files for $300M mixed securities shelf

2024-05-24 17:32:09 ET More on Cellectar Biosciences Cellectar Biosciences: Still Working On That Hit (Maintain Buy) Cellectar Biosciences GAAP EPS of -$0.74 misses by $0.18 Seeking Alpha’s Quant Rating on Cellectar Biosciences Read the full article ...

CLRB - Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis

2024-05-21 09:13:41 ET More on Eli Lilly Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety Eli Lilly: Don't Overpay For Miracle Drugs Eli Lilly’s tirzepatide cleared for diabetes t...
CLRB - Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

2024-05-20 13:02:41 ET Summary Cellectar Biosciences, Inc. is focused on developing a radiopharmaceutical for Waldenstrom's macroglobulinemia, a type of non-Hodgkin lymphoma. The company has positive topline data from a pivotal study, with a high response rate in patients with Wal...

CLRB - Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript

2024-05-14 13:05:17 ET Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Conference Call May 14, 2024, 08:30 AM ET Company Participants James Caruso - President and Chief Executive Officer Andrei Shustov - Senior Vice President, Medical Jarrod Longcor - Chief O...

CLRB - Cellectar Biosciences GAAP EPS of -$0.74 misses by $0.18

2024-05-14 06:44:49 ET More on Cellectar Biosciences Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Cellectar Biosciences Historical earnings data for Cellectar Biosciences Financial information for ...
CLRB - Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, develop...

CLRB - Cellectar Biosciences Q1 2024 Earnings Preview

2024-05-13 13:37:31 ET More on Cellectar Biosciences Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Cellectar Biosciences Historical earnings data for Cellectar Biosciences Financial information for ...

CLRB - Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating ...
Next 10